Vanguard Group Inc Oncternal Therapeutics, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.28 - $0.79 $905 - $2,554	-3,234 Reduced 0.11%	2,860,906 $972,000
Q4 2022 Feb 10, 2023	BUY	$0.86 - $22.2 $793 - $20,490	923 Added 0.03%	2,864,140 $2.86 Million
Q3 2022 Nov 14, 2022	BUY	$0.83 - $17.8 $604,406 - $13 Million	728,200 Added 34.11%	2,863,217 $2.55 Million
Q2 2022 Aug 12, 2022	SELL	$0.7 - $1.56 $133,348 - $297,176	-190,498 Reduced 8.19%	2,135,017 $2.37 Million
Q1 2022 May 13, 2022	BUY	$1.37 - $2.43 $263,298 - $467,019	192,189 Added 9.01%	2,325,515 $3.23 Million
Q4 2021 Feb 14, 2022	BUY	$2.27 - $4.39 $28,835 - $55,766	12,703 Added 0.6%	2,133,326 $4.84 Million
Q3 2021 Nov 12, 2021	BUY	$3.37 - $4.76 $43,887 - $61,989	13,023 Added 0.62%	2,120,623 $8.84 Million
Q2 2021 Aug 13, 2021	BUY	$4.75 - $9.39 $10 Million - $19.8 Million	2,107,600 New	2,107,600 $10 Million

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.